Working… Menu

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab (OCR-VAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04837651
Recruitment Status : Completed
First Posted : April 8, 2021
Last Update Posted : August 2, 2021
Information provided by (Responsible Party):
Dragonfly Research, LLC

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 1, 2021
Actual Study Completion Date : July 1, 2021